Development. Validation. Accessibility.
Helping to Improve Patient Outcomes through Liquid BiopsyOur Community
Driving Innovation in Liquid Biopsy to Advance Cancer Care
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium was launched in 2017 to accelerate the development, validation and clinical use of liquid biopsy assays to better inform medical decisions and improve patient care and outcomes. With input from regulatory, industry, and academic institution members, the BLOODPAC Consortium established that many of the challenges in the broader field of liquid biopsy resulted from a lack of collaboration, not any limitations of technology platforms or stalled science.
From Our Socials
How We Work
EVIDENCE GENERATION
Align around a framework for evidence generation to bring liquid biopsy into routine clinical practice.
BLOODPAC PORTAL
Enables community storing, sharing and analysis of liquid biopsy datasets for the community.
STAKEHOLDER ENGAGEMENT
Accelerate approval through stakeholder engagement.
“Cancer knows no borders, and neither should innovative technologies that can improve people's lives. BLOODPAC's work to foster a global dialogue on regulatory standards will help accelerate the process of bringing liquid biopsy to clinical settings around the world for patient benefit.”
JENNIFER DICKEY
Head, Regulatory and Quality at Personal Genome Diagnostics
